Suzanne Fanning, DO

Drs Richter and Fanning discuss next steps and future directions in the management of patients with relapsed/refractory multiple myeloma.

Experts summarize key points from routine clinical practice on use of ixazomib, lenalidomide, and dexamethasone (IRD) in patients with relapsed/refractory multiple myeloma.

Hematologic oncologists discuss toxicities seen with ixazomib, lenalidomide, and dexamethasone (IRd) compared with lenalidomide and dexamethasone (Rd).

Two experts discuss cytogenetic profiles in patients with relapsed/refractory multiple myeloma treated with either doublet or triplet therapy.

Data review of IRD vs Rd in patients with relapsed/refractory multiple myeloma who had a prior autologous stem cell transplant or extramedullary disease.

Experts provide commentary on the subgroup analyses from real-world data on use of ixazomib, lenalidomide, and dexamethasone compared with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Suzanne Fanning, DO, and Joshua Richter, MD discuss efficacy outcomes seen in a routine clinical practice study of ixazomib, lenalidomide and dexamethasone [IRD] compared with lenalidomide and dexamethasone [Rd] in patients with relapsed/refractory multiple myeloma.

Drs Fanning and Richter review the baseline characteristics of patients included in the routine clinical practice publication of ixazomib, lenalidomide, and dexamethasone [IRD] versus lenalidomide and dexamethasone [Rd] in patients with relapsed/refractory multiple myeloma.

Multiple myeloma experts share background for discussion of the recent publication, “Survival benefit of ixazomib, lenalidomide and dexamethasone [IRD] over lenalidomide and dexamethasone [Rd] in relapsed and refractory multiple myeloma patients in routine clinical practice.”

Multiple myeloma experts share background for discussion of the recent publication, “Survival benefit of ixazomib, lenalidomide and dexamethasone [IRD] over lenalidomide and dexamethasone [Rd] in relapsed and refractory multiple myeloma patients in routine clinical practice.”